These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21413054)

  • 21. On the use of nonparametric curves in phase I trials with low toxicity tolerance.
    Cheung YK
    Biometrics; 2002 Mar; 58(1):237-40. PubMed ID: 11890321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies.
    Zohar S; Chevret S
    Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
    Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
    Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A curve-free method for phase I clinical trials.
    Gasparini M; Eisele J
    Biometrics; 2000 Jun; 56(2):609-15. PubMed ID: 10877324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
    Tang N; Wang S; Ye G
    BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
    Liu S; Pan H; Xia J; Huang Q; Yuan Y
    Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
    Ji Y; Wang SJ
    J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using the time-to-event continual reassessment method in the presence of partial orders.
    Wages NA; Conaway MR; O'Quigley J
    Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent whole brain radiotherapy and bortezomib for brain metastasis.
    Lao CD; Friedman J; Tsien CI; Normolle DP; Chapman C; Cao Y; Lee O; Schipper M; Van Poznak C; Hamstra D; Lawrence T; Hayman J; Redman BG
    Radiat Oncol; 2013 Aug; 8():204. PubMed ID: 23965287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size formulae for the Bayesian continual reassessment method.
    Cheung YK
    Clin Trials; 2013; 10(6):852-61. PubMed ID: 23965547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.